NECC Fungal Meningitis Outbreak Litigation: Infection Control Failures and Legal Outcomes

Overview of the NECC Fungal Meningitis Outbreak

The New England Compounding Center (NECC) fungal meningitis outbreak of 2012 is widely recognized as one of the most significant healthcare-associated infection cases in the United States. NECC, a compounding pharmacy based in Framingham, Massachusetts, distributed contaminated preservative-free methylprednisolone acetate (MPA) steroid injections nationwide. Patients who received these injections developed fungal meningitis and other severe infections. According to data reported by the Centers for Disease Control and Prevention (CDC), 753 individuals across 20 states were affected, and 64 deaths were officially confirmed.

The outbreak highlighted major deficiencies in sterile compounding practices, infection control, and pharmacy oversight. Investigators documented concerns such as inadequate sterilization, poorly maintained cleanrooms, and deviations from USP <797> standards. These findings resulted in federal criminal prosecutions, extensive multidistrict litigation (MDL), and new regulatory measures. The NECC litigation remains a reference point for understanding how expert and government witness testimony informs courts when addressing complex scientific and regulatory issues.

Key Developments in the NECC Outbreak Litigation

September–October 2012 – Outbreak Identification, Recalls, and FDA Oversight

In September 2012, clusters of unusual fungal meningitis cases were reported in several states. CDC investigations determined that contaminated steroid injections produced by NECC were the source of the infections. This discovery initiated a national public health emergency and subsequent litigation. On September 26, 2012, NECC initiated a recall of three lots of MPA. On October 6, 2012, the recall was expanded to cover all NECC products. FDA inspections identified widespread problems in the facility, including sterility failures and unsafe cleanroom conditions. These findings became central evidence in civil actions and criminal cases.

Late 2012–2013 – Congressional Oversight Hearings

Following the outbreak, congressional committees held oversight hearings to examine compounding pharmacy regulation. Dr. Lauren Smith, then Interim Commissioner of the Massachusetts Department of Public Health, testified before Congress about the state’s regulatory framework and oversight limitations. Her testimony was part of the legislative fact-finding process and was not connected to either plaintiffs or defendants in litigation. These hearings provided a policy backdrop that contributed to later regulatory reforms.

2013–2014 – Civil MDL Formation and Federal Indictment

In 2013, numerous lawsuits filed by patients and families were consolidated into Multidistrict Litigation (MDL No. 1:13-md-02419-FDS) in the District of Massachusetts. In December 2014, a federal grand jury issued indictments against several NECC executives, including Barry Cadden (co-owner) and Glenn Chin (head pharmacist). The charges included racketeering, mail fraud, and predicate acts of second-degree murder under the RICO statute. The inclusion of homicide allegations within the racketeering framework reflected the severity with which the federal government viewed the case.

2017–2018 – Federal Convictions and Sentences

In 2017, Barry Cadden was convicted of racketeering, mail fraud, and related offenses. He was acquitted of the RICO murder predicate acts and was sentenced to nine years in federal prison. In October 2017, Glenn Chin was convicted of racketeering, mail fraud, and related offenses; in January 2018 he was sentenced to eight years in federal prison. These convictions demonstrated that violations in compounding pharmacy operations could carry criminal consequences when linked to widespread patient harm.

2021 – Resentencing Following Appeals

After the First Circuit vacated their original sentences, Barry Cadden was resentenced to 174 months (14.5 years) on July 7, 2021, and Glenn Chin was resentenced to 126 months (10.5 years) on July 21, 2021; the appellate court later affirmed Chin's new sentence in 2022. This adjustment underscored the seriousness with which federal courts addressed healthcare-related criminal liability.

2015 – $200 Million Civil Settlement Fund

Through bankruptcy proceedings, a $200 million victim compensation fund was approved in 2015 to provide restitution to affected patients and families. This settlement remains one of the largest compensation structures in healthcare-related litigation and illustrates how bankruptcy processes can be used to distribute funds in mass-tort cases.

2024 – State-Level Manslaughter Convictions

In 2024, Barry Cadden entered a plea of no contest in Michigan to 11 counts of involuntary manslaughter arising from patient deaths linked to NECC injections. He was sentenced to 10–15 years in state prison, served concurrently with his federal term. In a separate proceeding, Glenn Chin also entered a plea in Michigan and received a sentence of 7.5 to 15 years. These state-level cases reflected an additional layer of accountability, complementing the earlier federal proceedings.

Role of Expert and Government Witness Testimony in the NECC Case

Testimony from experts and government officials played an important role in explaining technical, scientific, and regulatory issues:

• Infection Control Expert Witness – Commonly provide analysis on cleanroom design, sterile compounding practices, and air-handling systems, helping courts understand how deficiencies contribute to contamination.
• Epidemiology Expert Witness (CDC, Prosecution Witness): Dr. Benjamin Park, a physician with the CDC, testified as a government witness for the prosecution in the federal criminal trial. He described the CDC’s epidemiological investigation and explained how patient clusters across states were traced to NECC’s contaminated steroid injections. His testimony helped establish causation, which was essential for the government’s case.
• Public Health Expert Witness (Congressional Witness): Dr. Lauren Smith, then Interim Commissioner of the Massachusetts Department of Public Health, testified before Congress in oversight hearings. Her testimony highlighted state-level regulatory limitations but was not connected to litigation or tied to either plaintiffs or defendants.
• Pharmaceutical Regulation Expert Witness (FDA, Prosecution Witness): Dr. Janet Woodcock, Director of the FDA’s Center for Drug Evaluation and Research, testified as a government witness for the prosecution at the federal trial. She explained the limits of FDA authority over compounding pharmacies at the time of the outbreak. Her testimony supported the prosecution’s argument that NECC’s unsafe practices operated in a regulatory gap.
• Medical Expert Witness in Neurology and Infectious Disease – In civil proceedings, medical experts typically address disease progression, long-term complications, and mortality risks, which are central to assessing damages.

Legal Insights for Attorneys and Litigators

• Compliance with Infection Control Standards: Departures from USP <797> formed a critical part of establishing negligence and liability in civil litigation.
• Coordination Between Public Health and Legal Systems: The collaboration among the CDC, FDA, and state authorities generated evidence later applied in both civil and criminal proceedings.
• Regulatory Developments Post-NECC: The Drug Quality and Security Act of 2013 introduced §503B outsourcing facilities, requiring larger compounders to follow Current Good Manufacturing Practices (CGMP).
• Mass-Tort Settlement Structures: The $200 million bankruptcy settlement illustrated how compensation funds may be structured in large-scale public health litigation.

Conclusion

The NECC fungal meningitis outbreak litigation remains a defining case where healthcare practices, law, and public health oversight intersected. It demonstrated how failures in compounding pharmacy operations can result in widespread harm, federal and state criminal prosecutions, and long-term regulatory changes. Expert testimony and government witness contributions were central in explaining causation, clarifying oversight gaps, and supporting both civil compensation and criminal accountability. For legal professionals, the case provides an instructive example of how infection control failures may evolve into high-impact litigation with lasting consequences.